RELMADA THERAPEUTICS, INC. Proceeds from Sale of Short-term Investments
RELMADA THERAPEUTICS, INC. (RLMD) reported Proceeds from Sale of Short-term Investments of $56.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfShortTermInvestments · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2026-06-30 was $42.34M, a 504.83% increase year-over-year.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2026-03-31 was $14.29M, a 9.83% decline year-over-year.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2025-12-31 was $5.86M, a 51.20% decline year-over-year.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for the quarter ending 2025-09-30 was $6.99M, a 63.71% decline year-over-year.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2025 was $35.69M, a 43.92% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2024 was $63.64M, a 54.84% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2023 was $140.92M, a 110.24% increase from fiscal 2022.
- RELMADA THERAPEUTICS, INC. proceeds from sale of short-term investments for fiscal 2022 was $67.03M, a 60.31% decline from fiscal 2021.
| Period end | Proceeds from Sale of Short-term Investments 3 month | Proceeds from Sale of Short-term Investments 6 month | Proceeds from Sale of Short-term Investments 9 month | Proceeds from Sale of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $56.63M 10-Q · filed 2026-08-06 | $62.48M derived: sum of 3 quarters · filed 2026-08-06 | $69.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.29M 10-Q · filed 2026-05-12 | $20.15M derived: sum of 2 quarters · filed 2026-05-12 | $27.13M derived: sum of 3 quarters · filed 2026-05-12 | $34.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $12.84M derived: sum of 2 quarters · filed 2026-03-19 | $19.84M derived: sum of 3 quarters · filed 2026-08-06 | $35.69M 10-K · filed 2026-03-19 |
| 2025-09-30 | $6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $13.99M derived: sum of 2 quarters · filed 2026-08-06 | $29.83M 10-Q · filed 2025-11-13 | $41.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.85M 10-Q · filed 2026-08-06 | $34.85M derived: sum of 3 quarters · filed 2026-08-06 | $54.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.85M 10-Q · filed 2026-05-12 | $27.85M derived: sum of 2 quarters · filed 2026-05-12 | $47.10M derived: sum of 3 quarters · filed 2026-05-12 | $62.42M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $31.26M derived: sum of 2 quarters · filed 2026-03-19 | $46.57M derived: sum of 3 quarters · filed 2026-03-19 | $63.64M 10-K · filed 2026-03-19 |
| 2024-09-30 | $19.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $34.57M derived: sum of 2 quarters · filed 2025-11-13 | $51.64M 10-Q · filed 2025-11-13 | $92.69M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $15.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $32.39M 10-Q · filed 2025-08-07 | $73.44M derived: sum of 3 quarters · filed 2025-08-07 | $88.87M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $17.07M 10-Q · filed 2025-05-12 | $58.13M derived: sum of 2 quarters · filed 2025-05-12 | $73.56M derived: sum of 3 quarters · filed 2025-05-12 | $83.22M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $41.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $56.49M derived: sum of 2 quarters · filed 2025-03-27 | $66.15M derived: sum of 3 quarters · filed 2025-03-27 | $140.92M 10-K · filed 2025-03-27 |
| 2023-09-30 | $15.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $25.09M derived: sum of 2 quarters · filed 2024-11-07 | $99.86M 10-Q · filed 2024-11-07 | $106.51M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $9.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $84.43M 10-Q · filed 2024-08-07 | $91.07M derived: sum of 3 quarters · filed 2024-08-07 | $128.21M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $74.77M 10-Q · filed 2024-05-08 | $81.42M derived: sum of 2 quarters · filed 2024-05-08 | $118.55M derived: sum of 3 quarters · filed 2024-05-08 | $125.91M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $43.78M derived: sum of 2 quarters · filed 2024-03-19 | $51.14M derived: sum of 3 quarters · filed 2024-03-19 | $67.03M 10-K · filed 2024-03-19 |
| 2022-09-30 | $37.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $44.49M derived: sum of 2 quarters · filed 2023-11-08 | $60.38M 10-Q · filed 2023-11-08 | $109.70M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $7.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $23.24M 10-Q · filed 2023-08-08 | $72.57M derived: sum of 3 quarters · filed 2023-08-08 | $125.68M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $15.89M 10-Q · filed 2023-05-11 | $65.21M derived: sum of 2 quarters · filed 2023-05-11 | $118.33M derived: sum of 3 quarters · filed 2023-05-11 | $148.62M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $49.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $102.44M derived: sum of 2 quarters · filed 2023-03-23 | $132.73M derived: sum of 3 quarters · filed 2023-03-23 | $168.86M 10-K · filed 2023-03-23 |
| 2021-09-30 | $53.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $83.41M derived: sum of 2 quarters · filed 2022-11-10 | $119.54M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $30.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $66.43M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $36.13M 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $30.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $53.38M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $22.39M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |